ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1578

Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study

Agnes Szentpetery1, Eric J. Heffernan2, Muhammad Haroon3, Phil Gallagher1, Anne-Marie Baker1, Martina Cooney1 and Oliver FitzGerald1, 1Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 2Radiology, St. Vincent's University Hospital, Dublin, Ireland, 3Newmarket On Fergus, Cork University Hospital, Cork, Ireland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Abatacept, MRI, psoriatic arthritis and synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose

Abatacept is a soluble, fully human fusion protein which selectively inhibits T-cell activation via the CD80/CD86:CD28 co-stimulation pathway and decreases serum levels of inflammatory cytokines and proteins implicated in the pathogenesis of psoriatic arthritis (PsA). Improvement in skin psoriasis has been shown with abatacept treatment previously with greatest reduction in PASI using 3 mg/kg dose.  It has been proposed that 10 mg/kg of abatacept, the approved dose for rheumatoid arthritis may be an effective treatment choice for PsA.

The objectives of the study were (1) to study both skin and joint-related clinical outcomes prior to and 6 months after introducing abatacept treatment in PsA; (2) to investigate MRI changes of an inflamed knee joint over time in PsA patients on abatacept.

Methods

Biological treatment-naïve PsA patients fulfilling the CASPAR criteria with active disease for > 3 months (>3 swollen and >3 tender joints) with clinical synovitis of a knee and the presence of a psoriatic skin lesion were enrolled to the study. Patients were randomised to receive abatacept 3mg/kg or placebo infusion on day 1, 15 and 29; thereafter abatacept 10mg/kg was administered every 28 days for 5 months. A stable dose of methotrexate (7.5-25 mgs/week) for > 3 months prior to randomization was the only concomitant DMARD permitted in the study. Ga-enhanced MRI of the same involved knee was performed at baseline, 2 and 6 months and scored using the PsAMRIS method by one consultant radiologist. For the semi-quantitative method each knee was divided into 4 anatomical regions; medial (MED) and lateral (LAT) parapateller recesses, intercondylar notch (ICN) and suprapatellar pouch (SPP). A synovitis score ranging from 0 to 3 was assigned to each region and then added for a total synovitis score (MRS) ranging from 0 to 12 per knee.

Results

15 patients (8 female/ 7 male) with mean age of 44.6 (±14.6) years were randomized by June 2014. Four (27%) patients were on methotrexate, the remainder did not receive any DMARDs during the study.

At baseline, mean DAS28-ESR was 4.9±1 and DAS28-CRP was 4.7±0.9. Median PASI, HAQ, PsAQol and DLQI were 3.8 (0-16.2), 1 (0-2.125), 10 (1-17) and 3 (0-27) respectively. Mean synovitis scores at MED, LAT, ICN and SPP regions were 2.07 (±0.9), 2.21 (±0.9), 1.4 (±0.8) and 1.85(±1) respectively at baseline, mean MRS was 7.6 (±3.4).

As per EULAR criteria 87.5 % of patients responded to the treatment at 6 months and 75% were good responders. Patients’ TJC68, SJC68, duration of morning stiffness, global health score, DAS28-ESR, DAS28-CRP, HAQ and PsAQol reduced significantly at 6 months compared to baseline. Median MRS decreased over the study period and was significantly lower at 6 months compared to baseline (p=0.016).

Conclusion

Six months of abatacept treatment reduced synovitis scores as assessed by MRI. The results of our study suggest that 10 mg/kg of abatacept is a potent treatment option in PsA.


Disclosure:

A. Szentpetery,
None;

E. J. Heffernan,
None;

M. Haroon,
None;

P. Gallagher,
None;

A. M. Baker,
None;

M. Cooney,
None;

O. FitzGerald,

Pfizer, Abbott, BMS, MSD, Roche, UCB,

2,

Pfizer, Abbott, BMS, MSD, Janssen, Roche ,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abatacept-improves-synovitis-as-assessed-by-magnetic-resonance-imaging-mri-in-psoriatic-arthritis-preliminary-analysis-from-a-single-centre-placebo-controlled-crossover-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology